 | Up a level |
Journal Article
Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S. and Heinemann, V (2021). Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur. J. Cancer, 146. S. 95 - 107. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V and Kunzmann, V (2022). Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open, 7 (4). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Kruger, S. F., Lohneis, A., Abendroth, A., Berger, A. W., Ettrich, T. J., Waidmann, O., Kapp, M., Steiner, B., Kumbrink, J., Reischer, A., Haas, M., Westphalen, C. B., Zhang, D., Miller-Phillips, L., Burger, P. J., Kobold, S., Werner, J., Subklewe, M., Von Bergwelt-Baildon, M., Kunzmann, V, Seufferlein, T., Siveke, J. T., Sinn, M., Heinemann, V, Ormanns, S. and Boeck, S. (2022). Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029